Affordable Access

Publisher Website

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Authors
  • 1
Type
Published Article
Journal
Journal of Clinical Oncology
1527-7755
Publisher
American Society of Clinical Oncology
Publication Date
Volume
27
Issue
4
Pages
491–497
Identifiers
DOI: 10.1200/JCO.2008.16.4459
PMID: 19075280
Source
Medline

Abstract

Sequential therapy with F-->C-->R yields improvement in quality of response, with many patients achieving a PCR-negative state.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments